| The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri, G Dusheiko, E Bugianesi, ... The Lancet 399 (10319), 61-116, 2022 | 330 | 2022 |
| Understanding barriers to hepatitis C virus care and stigmatization from a social perspective C Treloar, J Rance, M Backmund Clinical Infectious Diseases 57 (suppl_2), S51-S55, 2013 | 206 | 2013 |
| Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia A Doab, C Treloar, GJ Dore Clinical Infectious Diseases 40 (Supplement_5), S313-S320, 2005 | 197 | 2005 |
| Perceptions of discriminatory treatment by staff as predictors of drug treatment completion: Utility of a mixed methods approach L Brener, W Von Hippel, C Von Hippel, I Resnick, C Treloar Drug and Alcohol Review 29 (5), 491-497, 2010 | 190 | 2010 |
| Addiction stigma and the biopolitics of liberal modernity: A qualitative analysis S Fraser, K Pienaar, E Dilkes-Frayne, D Moore, R Kokanovic, C Treloar, ... International Journal of Drug Policy 44, 192-201, 2017 | 189 | 2017 |
| The social production of hepatitis C risk among injecting drug users: a qualitative synthesis T Rhodes, C Treloar Addiction 103 (10), 1593-1603, 2008 | 151 | 2008 |
| Single index of multimorbidity did not predict multiple outcomes JE Byles, C D'Este, L Parkinson, R O'Connell, C Treloar Journal of clinical epidemiology 58 (10), 997-1005, 2005 | 139 | 2005 |
| Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study M Alavi, J Grebely, M Micallef, AJ Dunlop, AC Balcomb, CA Day, ... Clinical Infectious Diseases 57 (suppl_2), S62-S69, 2013 | 137 | 2013 |
| Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework E Day, M Hellard, C Treloar, J Bruneau, NK Martin, A Øvrehus, O Dalgard, ... Liver International 39 (1), 20-30, 2019 | 135 | 2019 |
| The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis C Treloar, T Rhodes Qualitative Health Research 19 (9), 1321-1334, 2009 | 128 | 2009 |
| Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals C Treloar, J Newland, J Rance, M Hopwood Journal of viral hepatitis 17 (12), 839-844, 2010 | 123 | 2010 |
| ‘Spoiled identity’in hepatitis C infection: The binary logic of despair S Fraser, C Treloar Critical Public Health 16 (2), 99-110, 2006 | 116 | 2006 |
| Beyond deficit:‘Strengths‐based approaches’ in Indigenous health research J Bryant, R Bolt, JR Botfield, K Martin, M Doyle, D Murphy, S Graham, ... Sociology of health & illness 43 (6), 1405-1421, 2021 | 112 | 2021 |
| Trust and people who inject drugs: The perspectives of clients and staff of Needle Syringe Programs C Treloar, J Rance, K Yates, L Mao International Journal of Drug Policy 27, 138-145, 2016 | 112 | 2016 |
| “We are people too”: Consumer participation and the potential transformation of therapeutic relations within drug treatment J Rance, C Treloar International Journal of Drug Policy 26 (1), 30-36, 2015 | 112 | 2015 |
| Needle sharing in regular sexual relationships: an examination of serodiscordance, drug using practices, and the gendered character of injecting J Bryant, L Brener, P Hull, C Treloar Drug and alcohol dependence 107 (2-3), 182-187, 2010 | 105 | 2010 |
| Pleasure and drugs M Holt, C Treloar International Journal of Drug Policy 19 (5), 2008 | 104 | 2008 |
| Equity of access to treatment, and barriers to treatment for illicit drug use in Australia E Digiusto, C Treloar Addiction 102 (6), 958-969, 2007 | 104 | 2007 |
| Some characteristics of early‐onset injection drug users prior to and at the time of their first injection J Abelson, C Treloar, J Crawford, S Kippax, I Van Beek, J Howard Addiction 101 (4), 548-555, 2006 | 102 | 2006 |
| Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs? A Madden, M Hopwood, J Neale, C Treloar PloS one 13 (11), e0207226, 2018 | 101 | 2018 |
